Northeast Ohio Medical University

Northeast Ohio Medical University, doing business as Neomed, a state-controlled U.S. government entity and Ohio institution of higher learning, operates as a federal grant recipient and contract prime delivering military medical education services and biomedical research to federal agencies, with 87 percent of recent awards held as prime positions and 84 percent of contract footprint concentrated in Navy medical student tuition and fees.

Neomed is an ineligible entity for SBA certifications as a government-owned institution. The university delivers specialized medical education to military personnel under tuition and fee contracts covering degree programs in medicine, pharmacy, dentistry, and related health professions, and conducts federally funded biomedical research across neuroscience, cardiovascular biology, immunology, aging, and orthopedic disease mechanisms. Representative contract work includes a $378,691 delivery order from the Department of the Navy on May 5, 2026, for military medical student tuition and fees covering June 2026 through June 2027, a $473,915 Navy order dated July 1, 2025, for annual tuition and educational services, and a $647,382 Navy tuition and fees order from July 2024. Representative grant work includes a $626,200 National Institute of Child Health and Human Development award (CFDA 93.865) on August 20, 2026, investigating aspiration-driven lung pathophysiology in term and preterm infant models through animal studies, a $631,040 National Institute on Deafness and Other Communication Disorders award (CFDA 93.173) on February 1, 2026, examining metabotropic glutamate receptor function in auditory brainstem sound localization circuits, and a $584,330 National Institute of Arthritis and Musculoskeletal and Skin Diseases award (CFDA 93.846) on September 15, 2025, addressing mitochondrial DNA leakage in intervertebral disc degeneration.

Customer concentration is heavily weighted toward the Navy. The top five funding agencies account for 51 percent of awards by count, led by the Department of the Navy Bureau of Medicine and Surgery (50 awards, $3.7 million combined potential value), the National Institutes of Health overall (27 awards), the National Institute on Deafness and Other Communication Disorders (22 awards), the Health Resources and Services Administration (18 awards), and the National Heart Lung and Blood Institute (15 awards). The Navy's concentration dominates the contract footprint; 84 percent of contract awards are tuition and fee orders for military medical education placed against Neomed's single-award Basic Ordering Agreement with the Bureau of Medicine and Surgery running through March 31, 2035, established April 1, 2025.

Neomed holds a single-award Basic Ordering Agreement (N0018925GZ031) with the Navy Bureau of Medicine and Surgery with no stated ceiling value and performance through March 31, 2035. Two task orders under this vehicle carry $853 thousand in combined potential value. Additional Navy IDCs referenced in vehicle holdings include N0001486K0664 and N0014098G2502, each supporting one to three task orders.

Recent activity shows year-over-year growth through 2024 (11 awards in 2022, 22 in 2024), with modest decline to 18 awards in 2025 and 9 as of August 2026. Nine awards (combined potential value $379 thousand) reach completion within the next twenty-four months, creating modest recompete exposure. Neomed's combined dollars obligated across all awards total $229.8 million, reflecting significant back-billing or invoiced revenue against smaller stated potential values across the historical footprint.

In its subcontractor role, Neomed participates as a sub-recipient on research grants from Case Western Reserve University (multiple subawards spanning clinical translational science and cardiovascular research), University of Michigan (auditory neuroscience projects including VIP and NPY neuron analysis in the inferior colliculus), Florida State University (auditory brainstem physiology and genetically modified gerbil models for hearing research), Kent State University (proteomics analysis and antibacterial nanoparticle development), Carnegie Mellon University (auditory cortex recording and informational masking tasks), and Cleveland Clinic Lerner College of Medicine (liver fibrosis and metabolic disease mechanisms). Neomed also participates in subawards from the Ohio Department of Mental Health on annual mental health block grant awards and state opioid response programs.

Neomed's grant footprint spans the National Institutes of Health (neuroscience, aging, cardiovascular, musculoskeletal research; CFDA 93.8xx series), the National Science Foundation (geosciences; CFDA 47.050), the Defense Health Agency (military research; CFDA 12.420), the Bureau of Health Professionals (workforce development; HRSA), the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273), and state grant programs through the Ohio Department of Mental Health and Ohio Department of Higher Education. Representative grants include work on Alzheimer's disease pathophysiology, Parkinson's disease cognitive dysfunction, auditory brainstem circuit development, developmental neurobiology (primate arboreal locomotion risk assessment), infant feeding biomechanics, and osteoarthritis therapeutics.

Neomed's award footprint is primarily academic and research-oriented. Top NAICS category is Colleges, Universities, and Professional Schools (51 awards); top PSC category is Education/Training—Tuition/Registration/Membership Fees (57 awards), with R&D—Defense Other (Basic Research) accounting for 5 awards. The footprint reflects a health sciences university model: military medical education contracts dominate contract revenue, while biomedical research grants constitute the bulk of award count and longer-term commitments. Neomed has also launched a new Doctor of Dental Medicine program through the Bitonte College of Dentistry, supported by $6 million in Congressional Directed Spending, a $10 million philanthropic gift, and $1 million in Ohio state appropriations.